Nutex Health, Inc. (NUTX) Stock Forecast
Data as of Aug 1, 2026Healthcare · Current price $148.19 (-0.13%)
Price Target Range
Consensus Price Target Over Time
Analyst Rating Distribution
Last 3 Months
6-Month Trend
Latest Analyst Forecasts
Price targets issued by Wall Street analysts. Upside calculated against today's price.
| Date | Analyst | Firm | Price Target | Upside |
|---|---|---|---|---|
| Sep 18, 2024 | Anthony Vendetti | Maxim Group | $45.00 | -69.6% |
Top Analysts Covering NUTX
NUTX vs Sector & Market
| Metric | NUTX | Healthcare Avg | Large Cap Avg |
|---|---|---|---|
| Analyst Rating | — | 2.25 | 2.42 |
| Analyst Count | — | 8 | 19 |
| Target Upside | +58.6% | +16316.1% | +17.1% |
| P/E Ratio | 11.51 | 3.00 | 43.33 |
Revenue Estimates
| Period | Low | Avg | High | # |
|---|---|---|---|---|
| 2026-09-30 | $205M | $222M | $245M | 1 |
| 2026-12-31 | $221M | $239M | $264M | 2 |
| 2027-12-31 | $940M | $947M | $955M | 2 |
EPS Estimates
| Period | Low | Avg | High | # |
|---|---|---|---|---|
| 2026-09-30 | $3.19 | $3.55 | $4.03 | 1 |
| 2026-12-31 | $3.82 | $4.25 | $4.83 | 1 |
| 2027-12-31 | $16.79 | $17.55 | $18.62 | 1 |
Frequently Asked Questions
What is the analyst consensus for NUTX?
The consensus among 0 analysts covering Nutex Health, Inc. (NUTX) is — with an average price target of $205.00.
What is the highest price target for NUTX?
The highest price target for NUTX is $45.00, set by Anthony Vendetti at Maxim Group on 2024-09-18.
What is the lowest price target for NUTX?
The lowest price target for NUTX is $45.00, set by Anthony Vendetti at Maxim Group on 2024-09-18.
How many analysts cover NUTX?
0 analysts have issued ratings for Nutex Health, Inc. in the past 12 months.
Is NUTX a buy or sell right now?
Based on 0 analyst ratings, NUTX has a consensus rating of — with a +58.6% upside to the consensus target of $205.00.
What are the earnings estimates for NUTX?
Analysts estimate NUTX will report EPS of $3.55 for the period ending 2026-09-30, with revenue estimated at $222M.
Related Stock Forecasts
Data updated daily. Analyst price targets sourced from public filings and broker reports. Not investment advice.